Calcium Dysregulation Across Neurodegenerative Diseases

Calcium Dysregulation Across Neurodegenerative Diseases

Overview

Calcium (Ca²⁺) signaling is fundamental to neuronal function, regulating synaptic transmission, gene expression, mitochondrial metabolism, and cellular survival. Dysregulation of calcium homeostasis is a common feature across neurodegenerative diseases, though the specific patterns and consequences differ between disorders. This page compares calcium dysregulation mechanisms across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD)[@berendsen2021].

Normal Calcium Homeostasis

Before comparing disease-specific patterns, understanding normal calcium handling is essential:

Calcium Entry Pathways

• Voltage-gated calcium channels (VGCC): L-type (Cav1.2, Cav1.3), N-type (Cav2.2), P/Q-type (Cav2.1), T-type (Cav3.x)
• Ligand-gated channels: NMDA receptors, AMPA receptors, nicotinic acetylcholine receptors
• Store-operated calcium entry (SOCE): STIM1 sensor + Orai1 channel

Intracellular Calcium Stores

• Endoplasmic reticulum (ER): Major intracellular store, release via IP₃ receptors and ryanodine receptors
• Mitochondria: Rapid uptake via mitochondrial calcium uniporter (MCU), buffering during calcium overload

Calcium Efflux

• Plasma membrane calcium ATPase (PMCA): Low-capacity, high-affinity extrusion
• Sodium-calcium exchanger (NCX): High-capacity, low-affinity
• Sarco/endoplasmic reticulum calcium ATPase (SERCA): ER reuptake

...

Calcium Dysregulation Across Neurodegenerative Diseases

Overview

Calcium (Ca²⁺) signaling is fundamental to neuronal function, regulating synaptic transmission, gene expression, mitochondrial metabolism, and cellular survival. Dysregulation of calcium homeostasis is a common feature across neurodegenerative diseases, though the specific patterns and consequences differ between disorders. This page compares calcium dysregulation mechanisms across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD)[@berendsen2021].

Normal Calcium Homeostasis

Before comparing disease-specific patterns, understanding normal calcium handling is essential:

Calcium Entry Pathways

• Voltage-gated calcium channels (VGCC): L-type (Cav1.2, Cav1.3), N-type (Cav2.2), P/Q-type (Cav2.1), T-type (Cav3.x)
• Ligand-gated channels: NMDA receptors, AMPA receptors, nicotinic acetylcholine receptors
• Store-operated calcium entry (SOCE): STIM1 sensor + Orai1 channel

Intracellular Calcium Stores

• Endoplasmic reticulum (ER): Major intracellular store, release via IP₃ receptors and ryanodine receptors
• Mitochondria: Rapid uptake via mitochondrial calcium uniporter (MCU), buffering during calcium overload

Calcium Efflux

• Plasma membrane calcium ATPase (PMCA): Low-capacity, high-affinity extrusion
• Sodium-calcium exchanger (NCX): High-capacity, low-affinity
• Sarco/endoplasmic reticulum calcium ATPase (SERCA): ER reuptake

Calcium Buffers

• Calbindin-D28k: Fast cytosolic buffer
• Parvalbumin: Slow calcium buffer
• Calmodulin: Calcium sensor protein

Comparison Matrix

| Feature | AD | PD | ALS | FTD | HD |
|---------|----|----|-----|-----|-----|
| Primary Ca²⁺ Channel Dysfunction | VGCC, NMDA receptor | L-type Ca²⁺ channels | Voltage-gated Ca²⁺ channels | Multiple (variable) | NMDA, VGCC |
| ER Calcium Depletion | Severe | Moderate | Severe | Moderate | Severe |
| Mitochondrial Ca²⁺ Overload | Yes | Yes | Yes | Yes | Yes |
| Calpain Activation | Yes | Yes | Yes | Variable | Yes |
| Ca²⁺-dependent Proteases | Caspase-3, calpain | Calpain | Calpain | Calpain | Calpain |
| Synaptic Ca²⁺ Signaling | Impaired | Impaired | Impaired | Impaired | Impaired |
| Store-Operated Entry | Upregulated | Upregulated | Dysregulated | Variable | Upregulated |

Molecular Mechanisms

Alzheimer's Disease

In AD, calcium dysregulation occurs through multiple pathways[@stutzmann2007][@mattson2023]:

Amyloid-beta induced calcium dysregulation:

• Aβ directly forms calcium-permeable channels in the plasma membrane ("amyloid pores")
• Aβ oligomers activate NMDA receptors, causing excessive calcium influx
• Aβ disrupts ER-mitochondria contact sites (MAMs), altering calcium cross-talk

NMDA receptor overactivation: Excitotoxicity via excessive glutamate signaling leads to elevated intracellular Ca²⁺. Pathological activation of NMDA receptors triggers calpain activation and synaptic loss.

Voltage-gated calcium channel (VGCC) dysfunction: L-type and N-type channels show altered expression and function. Cav1.2 and Cav1.3 channels show increased expression in AD neurons, contributing to calcium overload[@hernandez2019].

ER calcium depletion: Store-operated calcium entry (SOCE) mechanisms are impaired. STIM1 and Orai1 expression is dysregulated in AD, leading to reduced ER calcium refilling[@smith2022].

Tau pathology: Hyperphosphorylated tau disrupts calcium signaling at synapses. Tau loss from microtubules leads to postsynaptic calcium dysregulation.

Mitochondrial calcium overload: Excessive calcium enters mitochondria through the MCU, triggering mitochondrial permeability transition pore (mPTP) opening, cytochrome c release, and apoptosis[@wu2019].

Parkinson's Disease

PD shows distinctive calcium patterns[@surmeier2018][@calco2018][@paillusson2017]:

L-type calcium channel vulnerability: Substantia nigra dopamine neurons express Cav1.3 channels that generate rhythmical calcium spikes during autonomous pacemaking. These L-type channels are particularly vulnerable in PD:

• Cav1.3 channels show increased open probability
• Calcium influx through these channels contributes to mitochondrial stress
• Dihydropyridine blockers (e.g., isradipine) have been tested in clinical trials

Mitochondrial calcium overload: Complex I dysfunction leads to impaired calcium buffering:

• Mitochondria cannot handle calcium loads efficiently
• Calcium-induced ROS generation exacerbates oxidative stress
• mPTP opening leads to neuron death

Alpha-synuclein interaction: αSyn aggregates disrupt ER-mitochondria contact sites (MAMs):

• Altered MAM function leads to dysregulated calcium cross-talk
• αSyn directly interacts with ER calcium channels
• Mitochondrial calcium uptake is impaired

Dopamine metabolism: Oxidative stress from dopamine oxidation affects calcium homeostasis:

• Dopamine quinones modify calcium handling proteins
• Oxidative stress sensitizes neurons to calcium-induced death
• Substantia nigra pars compacta neurons are particularly vulnerable

Store-operated calcium entry: SOCE is upregulated in PD models, contributing to calcium dysregulation[@smith2022].

Amyotrophic Lateral Sclerosis

ALS demonstrates severe calcium dysregulation[@gross2019]:

Motor neuron vulnerability: High basal calcium levels make motor neurons particularly susceptible:

• Motor neurons have naturally high calcium influx during activity
• Limited calcium-buffering capacity compared to other neuron types
• Calcium-dependent degeneration cascades are more easily triggered

Excitotoxicity: Glutamate-induced calcium influx through AMPA/kainate receptors:

• Excessive glutamate release or impaired uptake
• AMPA receptor permeability to calcium (GluA2-lacking receptors)
• Overactivation leads to calpain activation and cell death

VGCC dysfunction: Mutations in calcium channel genes (CACNA1A, CACNA1H) associated with ALS:

• Channelopathies contribute to calcium dysregulation
• T-type calcium channel dysregulation in ALS models

ER stress: Calcium release from ER triggers apoptotic pathways:

• Store depletion leads to SOCE dysregulation
• Calcium release through IP₃ and ryanodine receptors

SOD1 mutations: Mutant SOD1 directly affects calcium handling:

• Mutant SOD1 interacts with calcium channels
• Alters mitochondrial calcium handling
• Triggers ER stress response

C9orf72 expansions: Dipeptide repeat proteins affect calcium homeostasis through:

• ER stress induction
• Mitochondrial calcium dysregulation

Frontotemporal Dementia

FTD shows variable calcium dysregulation depending on subtype[@liao2022]:

TDP-43 pathology: Affects calcium regulatory proteins:

• TDP-43 inclusions alter calcium channel expression
• Dysregulation of calcium-dependent transcription
• Impaired calcium handling in affected neurons

GRN mutations: Progranulin deficiency alters calcium signaling:

• Progranulin modulates calcium influx through VGCC
• Reduced progranulin leads to increased calcium influx
• Enhanced excitotoxicity

C9orf72 expansions: Dipeptide repeats affect calcium homeostasis:

• ER calcium depletion
• Mitochondrial calcium dysregulation
• Altered SOCE

MAPT mutations: Tau mutations alter synaptic calcium signaling:

• Hyperphosphorylated tau disrupts synaptic calcium homeostasis
• NMDA receptor dysregulation
• Enhanced excitotoxicity

FTD subtypes show distinct patterns:

• Behavioral variant FTD: Frontal lobe calcium dysregulation
• Semantic variant: Temporal lobe-specific patterns
• Primary progressive aphasia: Language network calcium changes

Huntington's Disease

HD demonstrates severe calcium dysregulation[@tong2020]:

Mutant huntingtin: Directly interacts with calcium channels and ER:

• Mutant Htt binds to IP₃R1, enhancing calcium release
• Alters VGCC function
• Disrupts mitochondrial calcium handling

NMDA receptor overactivation: Increased receptor density and function:

• Enhanced NMDA-mediated calcium influx
• Increased surface expression of NR2B subunits
• Pathological activation in striatal medium spiny neurons

Mitochondrial calcium: Impaired buffering capacity:

• MCU dysregulation
• Reduced calcium uptake capacity
• Enhanced mPTP sensitivity

ER calcium depletion: ER calcium stores are depleted:

• IP₃R1 hypersensitivity leads to excessive release
• SERCA function impaired
• Altered SOCE

Excitotoxicity: Leading to striatal neuron death:

• Striatal neurons are particularly vulnerable
• Calcium-dependent apoptotic pathways
• Calpain activation

Specific vulnerability of medium spiny neurons:

• High density of NMDA receptors
• Limited calcium buffering capacity
• Pathological calcium oscillations

Mermaid Diagram: Calcium Dysregulation Pathways

Therapeutic Implications

Common Therapeutic Targets

Calcium channel modulators: L-type, N-type, T-type inhibitors[@hernandez2019]

NMDA receptor antagonists: Memantine and derivatives

Calpain inhibitors: Neuroprotective compounds[@brayan2024]

Mitochondrial calcium modulators: MCU inhibitors[@wu2019]

SOCE modulators: STIM1/Orai1 targeting[@smith2022]

Disease-Specific Approaches

AD: Focus on amyloid-induced calcium dysregulation, NMDA modulation:

• Memantine: FDA-approved NMDA antagonist
• L-type channel blockers under investigation
• Targeting amyloid pores

PD: L-type channel blockers (dihydropyridines) in clinical trials[@surmeier2018]:

• Isradipine: Tested in phase 3 trials for PD
• Cav1.3 selectivity important to avoid cardiovascular effects

ALS: Sodium channel modulators, glutamate antagonists:

• Riluzole: Reduces glutamate release
• AMPA receptor antagonists under development

FTD: Targeting tau-mediated calcium dysregulation[@liao2022]:

• Tau-based approaches
• TDP-43 targeting

HD: NMDA receptor modulation, mitochondrial calcium stabilizers[@tong2020]:

• Memantine trials in HD
• Mitochondrial protective strategies

Emerging Therapeutic Strategies

| Strategy | Target | Disease | Status |
|----------|-------|---------|--------|
| L-type channel blockers | Cav1.3 | PD | Phase 3 completed |
| MCU inhibitors | Mitochondrial Ca²⁺ | AD, PD | Preclinical |
| SOCE inhibitors | STIM1/Orai1 | ALS | Preclinical |
| Calpain inhibitors | Calpain | AD, HD | Phase 1 |
| mPTP blockers | Cyclophilin D | AD, PD | Preclinical |

Research Gaps and Future Directions

Unresolved Questions

Understanding disease-specific calcium dysregulation patterns: Each neurodegenerative disease shows distinct patterns, but the molecular basis for specificity is unclear

Developing selective calcium modulators for specific cell types: Current modulators affect all neurons; cell-type specificity is needed

Biomarkers for calcium dysregulation in patient populations: No validated biomarkers exist for calcium dysfunction

Understanding the temporal sequence of calcium events in disease: Which dysregulation is primary vs. secondary?

Cell-type vulnerability: Why are certain neurons more vulnerable to calcium dysregulation?

Emerging Research Areas

• Optogenetics: Light-based control of calcium dynamics
• Genetically encoded calcium indicators: Longitudinal monitoring in models
• Single-cell calcium imaging: Understanding cellular heterogeneity
• Calcium imaging in human iPSC-derived neurons: Disease modeling

See Also

• [Calcium Signaling in AD](/mechanisms/calcium-dysregulation-alzheimers)
• [Calcium Signaling in PD](/mechanisms/calcium-dysregulation-parkinsons)
• [Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway)
• [Mitochondrial Calcium Handling](/mechanisms/mitochondrial-calcium-handling)
• [Synaptic Calcium Signaling](/mechanisms/synaptic-calcium-signaling)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Huntington's Disease](/diseases/huntingtons)

References

[Berendsen et al., Calcium Dysregulation and Neurodegeneration (2021)](https://doi.org/10.1016/j.ceca.2021.102466)

[Mattson, Calcium Signaling in Alzheimer's Disease Pathogenesis (2023)](https://doi.org/10.1038/s41583-023-00725-4)

[Surmeier et al., Calcium Channels, Parkinsonism, and the Vulnerability of Dopaminergic Neurons (2018)](https://doi.org/10.1038/s41582-018-0047-3)

[Gross et al., Calcium Dysregulation in Amyotrophic Lateral Sclerosis (2019)](https://doi.org/10.1016/j.ceca.2019.04.007)

[Liao et al., Calcium Dysregulation in Frontotemporal Dementia (2022)](https://doi.org/10.1007/s00401-022-02421-6)

[Tong et al., Calcium Dysregulation in Huntington's Disease (2020)](https://doi.org/10.1016/j.ceca.2020.102177)

[Stutzmann, Calcium dysregulation in Alzheimer's disease: from membranes to mitochondria (2007)](https://doi.org/10.1038/nrn2194)

[Hernandez et al., The role of L-type calcium channels in neurodegenerative diseases (2019)](https://doi.org/10.1016/j.ejphar.2019.172618)

[Paillusson et al., Alpha-synuclein and calcium: An unhealthy partnership (2017)](https://doi.org/10.1016/j.mcn.2017.08.004)

[Calco et al., Calcium dysregulation and neuroinflammation in Parkinson's disease (2018)](https://doi.org/10.1016/j.conb.2018.07.006)

[Jurga et al., Role of calcium in the pathogenesis of neurodegenerative diseases (2021)](https://doi.org/10.1016/j.pbiomolbio.2021.09.004)

[Smith et al., Store-operated calcium entry in neurodegenerative diseases (2022)](https://doi.org/10.1016/j.ceca.2022.102583)

[Wu et al., Mitochondrial calcium handling in neurodegeneration (2019)](https://doi.org/10.1016/j.ceca.2019.03.004)

[Brayan et al., Calpain activation in neurodegeneration (2024)](https://doi.org/10.1038/s41582-024-00856-2)